...
首页> 外文期刊>American Journal of Physiology >A1 adenosine receptor antagonism improves glucose tolerance in Zucker rats.
【24h】

A1 adenosine receptor antagonism improves glucose tolerance in Zucker rats.

机译:A1腺苷受体拮抗作用可改善Zucker大鼠的葡萄糖耐量。

获取原文
获取原文并翻译 | 示例

摘要

The A1 adenosine receptor (A1ar) antagonist 1,3-dipropyl-8-(p-acrylic)-phenylxanthine (BW-1433) was administered to lean and obese Zucker rats to probe the influence of endogenously activated A1ars on whole body energy metabolism. The drug induced a transient increase in lipolysis as indicated by a rise in serum glycerol in obese rats. The disappearance of the response by day 7 of chronic studies was accompanied by an increase in A1ar numbers. Glucose tolerance tests were administered to rats treated with BW-1433. Peak serum insulin levels and areas under glucose curves (AUGs) were 34 and 41% lower in treated obese animals than in controls, respectively, and 19 and 39% lower in lean animals. With chronic administration (6 wk), AUGs decreased 47 and 33% in obese and lean animals, respectively. There was no effect of BW-1433 in either lean or obese rats on weight gain or percent body fat. Thus the major sustained influence of whole body A1ar antagonism in both lean and obese animals was an increase in whole body glucose tolerance at lower levels of insulin.
机译:将A1腺苷受体(A1ar)拮抗剂1,3-二丙基-8-(对丙烯酸)-苯基黄嘌呤(BW-1433)施用给肥胖和肥胖的Zucker大鼠,以研究内源性活化的A1ars对全身能量代谢的影响。如肥胖大鼠的血清甘油升高所示,该药物引起脂解的短暂增加。在慢性研究的第7天,反应消失,伴随着A1ar数量的增加。对用BW-1433治疗的大鼠进行了糖耐量测试。治疗的肥胖动物的峰值血清胰岛素水平和葡萄糖曲线下面积(AUGs)分别比对照组低34%和41%,而瘦肉动物低19%和39%。长期服用(6周),肥胖和瘦肉动物的AUGs分别降低47%和33%。在瘦或肥胖的大鼠中,BW-1433对体重增加或体脂百分比没有影响。因此,在瘦肉和肥胖动物中,全身A1ar拮抗作用的主要持续影响是在较低胰岛素水平下全身葡萄糖耐量的增加。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号